Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 3 results

ea0050p399 | Thyroid | SFEBES2017

Autoantibodies to the thyrotropin receptor in Alemtuzumab-induced thyroid autoimmunity: determination of their biological activity, and possible role as predictive marker of disease

Muller Ilaria , Willis Mark , Healy Sarah , Nasser Taha , Zhang Lei , Draman Mohd Shazli , Taylor Peter , Robertson Neil , Ludgate Marian , Dayan Colin

Background: Alemtuzumab (ALTZ) is a humanised monoclonal anti-CD52 antibody used as effective treatment for relapsing/remitting multiple sclerosis (MS), causing panlymphopenia with subsequent lymphocyte repopulation. Unfortunately, around 40% of patients develop secondary humoral autoimmunity, mainly affecting the thyroid gland. Anti-thyrotropin-receptor (TSHR) autoantibodies (TRAb) can stimulate (TSAb), block (TBAb) or not affect (‘neutral’) TSHR function, with TSAb...
0 shares

ea0050p399 | Thyroid | SFEBES2017

Autoantibodies to the thyrotropin receptor in Alemtuzumab-induced thyroid autoimmunity: determination of their biological activity, and possible role as predictive marker of disease

Muller Ilaria , Willis Mark , Healy Sarah , Nasser Taha , Zhang Lei , Draman Mohd Shazli , Taylor Peter , Robertson Neil , Ludgate Marian , Dayan Colin

Background: Alemtuzumab (ALTZ) is a humanised monoclonal anti-CD52 antibody used as effective treatment for relapsing/remitting multiple sclerosis (MS), causing panlymphopenia with subsequent lymphocyte repopulation. Unfortunately, around 40% of patients develop secondary humoral autoimmunity, mainly affecting the thyroid gland. Anti-thyrotropin-receptor (TSHR) autoantibodies (TRAb) can stimulate (TSAb), block (TBAb) or not affect (‘neutral’) TSHR function, with TSAb...
0 shares

ea0044ep97 | (1) | SFEBES2016

Graves’ disease with fluctuating thyroid status and hypothyroidism with positive anti-TSH receptor antibody levels – distinctive autoimmune side-effects following alemtuzumab therapy for multiple sclerosis

Pariani Nadia , Willis Mark , Muller Ilaria , Healy Sarah , Nasser Taha , Jones Joanne , Chatterjee V. Krishna K. , Dayan Colin , Robertson Neil , Coles Alasdair , Moran Carla

Alemtuzumab, a highly effective, newly-licensed, treatment for multiple sclerosis (MS), is notably associated with Graves’ disease (GD), which reportedly has an indolent course.Methods: Case record review of patients who developed thyroid dysfunction (TD) after alemtuzumab treatment in Cambridge & Cardiff, to determine type, frequency and course of TD.Results: 41.8% (104/249; 81F, 23M) of alemtuzumab-treated patients devel...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more